AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
Measurable residual disease (MRD) in AML, assessed by multicolor flow cytometry, is an important prognostic factor. Progenitors are key populations in defining MRD, and cases of MRD involving these progenitors are calculated as percentage of WBC and referred to as white blood cell MRD (WBC-MRD). Two...
Main Authors: | Diana Hanekamp, Jesse M. Tettero, Gert J. Ossenkoppele, Angèle Kelder, Jacqueline Cloos, Gerrit Jan Schuurhuis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2597 |
Similar Items
-
MRD Tailored Therapy in AML: What We Have Learned So Far
by: Lok Lam Ngai, et al.
Published: (2021-01-01) -
MRD in AML: The Role of New Techniques
by: Maria Teresa Voso, et al.
Published: (2019-07-01) -
MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
by: Ilias Pessach, et al.
Published: (2022-09-01) -
Novel Tools for Diagnosis and Monitoring of AML
by: Francesca Guijarro, et al.
Published: (2023-05-01) -
MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)